PDL BioPharma (PDLI) Misses Q2 EPS by 21c, Revenues Beat

PDL BioPharma (NASDAQ: PDLI) reported Q2 EPS of ($0.11), $0.21 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $5.21 million versus the consensus estimate of $1.5 million.

"I am pleased with the significant progress we have made over the past couple of months in the execution of our monetization strategy," commented PDL's President and CEO Dominique Monnet. "We continue to focus on maximizing the net proceeds from the monetization of our assets for our stockholders, and I believe the actions we have taken so far have served them well. I would like to thank the PDL Board and team, our advisors and our LENSAR and Noden colleagues for their continued engagement, dedication and support."

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Z Squared outlines AI power strategy and Paradox Data acquisition